Flagship Harbor Advisors LLC Lowers Stock Position in Novo Nordisk A/S (NYSE:NVO)

Flagship Harbor Advisors LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 4.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,499 shares of the company’s stock after selling 584 shares during the period. Flagship Harbor Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,075,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of NVO. GSB Wealth Management LLC raised its holdings in Novo Nordisk A/S by 96.3% in the 4th quarter. GSB Wealth Management LLC now owns 24,394 shares of the company’s stock worth $2,098,000 after purchasing an additional 11,970 shares during the period. Linden Thomas Advisory Services LLC raised its stake in shares of Novo Nordisk A/S by 25.7% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 3,555 shares of the company’s stock worth $306,000 after buying an additional 726 shares during the period. Bennett Selby Investments LP lifted its position in shares of Novo Nordisk A/S by 7.9% during the 4th quarter. Bennett Selby Investments LP now owns 28,225 shares of the company’s stock valued at $2,428,000 after buying an additional 2,074 shares in the last quarter. Carr Financial Group Corp grew its stake in Novo Nordisk A/S by 14.0% in the 4th quarter. Carr Financial Group Corp now owns 2,393 shares of the company’s stock valued at $206,000 after acquiring an additional 293 shares during the period. Finally, Curated Wealth Partners LLC increased its holdings in Novo Nordisk A/S by 38.6% in the 4th quarter. Curated Wealth Partners LLC now owns 6,698 shares of the company’s stock worth $576,000 after acquiring an additional 1,865 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the topic of several recent analyst reports. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $87.45 on Tuesday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The stock has a market cap of $392.43 billion, a PE ratio of 28.30, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50 day moving average price of $95.35 and a 200 day moving average price of $114.80.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.